Drugs.com - Pharma Industry News

Efanesoctocog Alfa Not Cost-Effective for Prophylaxis in Hemophilia A

MONDAY, April 28, 2025 -- For U.S. patients with severe hemophilia A, prophylaxis with efanesoctocog alfa is neither conventionally nor distributionally cost-effective, according to a study published online April 22 in the Annals of Internal...

Apr 28, 2025 - 19:02
 0
Efanesoctocog Alfa Not Cost-Effective for Prophylaxis in Hemophilia A
MONDAY, April 28, 2025 -- For U.S. patients with severe hemophilia A, prophylaxis with efanesoctocog alfa is neither conventionally nor distributionally cost-effective, according to a study published online April 22 in the Annals of Internal...
Read More

Tags:

Previous Article

Early Combination of Lipid-Lowering Therapy Beneficial After Myocardial Infarction

Next Article

Recent Years Saw Increase in Youth With Anxiety, Depression

Related Posts

Melphalan/Hepatic Delivery System Beneficial for Metastatic Uveal Melanoma

Melphalan/Hepatic Delivery System Beneficial for Metast...

Apr 24, 2025  0

Moderately Preterm Birth Tied to Long-Term Cognitive Problems

Moderately Preterm Birth Tied to Long-Term Cognitive Pr...

Apr 25, 2025  0

Common Medications Tied to Older Age at Onset of Parkinson Disease

Common Medications Tied to Older Age at Onset of Parkin...

Apr 25, 2025  0